Free Trial
Final Hours! Save $100 on MarketBeat All Access Before 11:59 PM
  • 0Days
  • 0Hours
  • 0Minutes
  • 0Seconds
Lock In $149 Tonight
Claim MarketBeat All Access Sale Promotion

Regeneron Pharmaceuticals (REGN) Financials

Regeneron Pharmaceuticals logo
$638.88 0.00 (0.00%)
Closing price 05/22/2026 04:00 PM Eastern
Extended Trading
$634.44 -4.44 (-0.69%)
As of 05/22/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Regeneron Pharmaceuticals

Annual Income Statements for Regeneron Pharmaceuticals

This table shows Regeneron Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
636 896 1,199 2,444 2,116 3,513 8,075 4,338 3,954 4,413 4,505
Consolidated Net Income / (Loss)
636 896 1,199 2,444 2,116 3,513 8,075 4,338 3,954 4,413 4,505
Net Income / (Loss) Continuing Operations
636 896 1,199 2,444 2,116 3,513 8,075 4,338 3,954 4,413 4,505
Total Pre-Tax Income
1,225 1,330 2,079 2,554 2,429 3,810 9,326 4,859 4,199 4,780 5,231
Total Operating Income
1,252 1,331 2,080 2,534 2,210 3,577 8,947 4,739 4,047 3,991 3,578
Total Gross Profit
3,711 4,561 5,475 4,728 5,793 7,377 13,634 10,613 11,301 12,232 12,242
Total Revenue
4,104 4,860 5,872 5,146 6,558 8,497 16,072 12,173 13,117 14,202 14,343
Operating Revenue
4,029 4,860 5,872 5,146 6,558 8,497 16,072 12,173 13,117 14,202 14,343
Total Cost of Revenue
393 300 397 418 765 1,120 2,438 1,560 1,816 1,971 2,101
Operating Cost of Revenue
393 300 397 418 765 1,120 2,438 1,560 1,816 1,971 2,101
Total Operating Expenses
2,459 3,230 3,396 2,194 3,583 3,801 4,687 5,874 7,254 8,241 8,664
Selling, General & Admin Expense
839 1,178 1,320 1,127 1,342 1,346 1,825 2,116 2,631 2,954 2,700
Research & Development Expense
1,621 2,052 2,075 1,469 2,450 2,735 2,908 3,848 4,625 5,233 5,974
Other Operating Expenses / (Income)
- - - -402 -209 -280 -46 -90 -2.10 53 -10
Total Other Income / (Expense), net
-27 -1.80 -1.10 19 219 234 379 120 152 789 1,653
Interest Expense
- 7.20 25 28 30 57 57 59 73 55 44
Other Income / (Expense), net
-13 5.40 24 47 250 291 436 179 225 844 1,697
Income Tax Expense
589 434 880 109 313 297 1,251 520 246 367 726
Basic Earnings per Share
$6.17 $8.55 $11.27 $22.65 $19.38 $32.65 $76.40 $40.51 $37.05 $40.90 $43.07
Weighted Average Basic Shares Outstanding
103.06M 104.70M 106.30M 107.90M 109.20M 107.60M 105.70M 107.10M 106.70M 107.90M 104.60M
Diluted Earnings per Share
$5.52 $7.70 $10.34 $21.29 $18.46 $30.52 $71.97 $38.22 $34.77 $38.34 $41.48
Weighted Average Diluted Shares Outstanding
115.23M 116.30M 115.90M 114.80M 114.60M 115.10M 112.20M 113.50M 113.70M 115.10M 108.60M
Weighted Average Basic & Diluted Shares Outstanding
103.10M 104.70M 106.30M 109.28M 110.02M 107.13M 108.54M 109.33M 109.76M 109.32M 105.72M
Cash Dividends to Common per Share
- - - - - - - - - - $3.52

Quarterly Income Statements for Regeneron Pharmaceuticals

This table shows Regeneron Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders
1,008 1,160 722 1,432 1,341 918 809 1,392 1,460 845 727
Consolidated Net Income / (Loss)
1,008 1,160 722 1,432 1,341 918 809 1,392 1,460 845 727
Net Income / (Loss) Continuing Operations
1,008 1,160 722 1,432 1,341 918 809 1,392 1,460 845 727
Total Pre-Tax Income
1,111 1,148 701 1,628 1,493 958 905 1,519 1,763 1,044 831
Total Operating Income
1,111 973 751 1,070 1,180 990 592 1,080 1,027 880 643
Total Gross Profit
2,926 2,917 2,711 3,067 3,230 3,224 2,564 3,145 3,233 3,300 2,936
Total Revenue
3,363 3,434 3,145 3,547 3,721 3,789 3,029 3,676 3,754 3,884 3,605
Operating Revenue
3,363 3,434 3,145 3,547 3,721 3,789 3,029 3,676 3,754 3,884 3,605
Total Cost of Revenue
436 517 434 480 491 565 464 530 522 585 669
Operating Cost of Revenue
436 517 434 480 491 565 464 530 522 585 669
Total Operating Expenses
1,815 1,944 1,960 1,997 2,050 2,234 1,973 2,066 2,206 2,420 2,293
Selling, General & Admin Expense
641 738 689 759 714 792 633 634 658 775 648
Research & Development Expense
1,175 1,207 1,256 1,224 1,328 1,426 1,340 1,432 1,558 1,645 1,645
Total Other Income / (Expense), net
-0.20 175 -51 559 314 -32 313 439 737 164 188
Interest Expense
18 18 16 15 14 11 8.70 3.60 19 12 13
Other Income / (Expense), net
18 193 -35 573 327 -22 322 443 756 176 201
Income Tax Expense
103 -12 -21 196 152 40 96 127 303 199 104
Basic Earnings per Share
$9.48 $10.88 $6.70 $13.25 $12.40 $8.55 $7.58 $13.24 $14.09 $8.16 $6.99
Weighted Average Basic Shares Outstanding
106.30M 106.70M 107.80M 108.10M 108.10M 107.90M 106.70M 105.10M 103.60M 104.60M 104M
Diluted Earnings per Share
$8.89 $10.21 $6.27 $12.41 $11.54 $8.12 $7.27 $12.81 $13.62 $7.78 $6.75
Weighted Average Diluted Shares Outstanding
113.40M 113.70M 115.10M 115.40M 116.20M 115.10M 111.20M 108.60M 107.20M 108.60M 107.70M
Weighted Average Basic & Diluted Shares Outstanding
108.95M 109.76M 110.19M 110.23M 109.89M 109.32M 107.97M 105.99M 105.10M 105.72M 104.84M
Cash Dividends to Common per Share
- - - - - - - $0.88 - - $0.94

Annual Cash Flow Statements for Regeneron Pharmaceuticals

This table details how cash moves in and out of Regeneron Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
160 -261 278 655 150 577 691 221 -382 -249 635
Net Cash From Operating Activities
1,331 1,486 1,307 2,195 2,430 2,618 7,081 5,015 4,594 4,421 4,979
Net Cash From Continuing Operating Activities
1,331 1,486 1,307 2,195 2,430 2,618 7,081 5,015 4,594 4,421 4,979
Net Income / (Loss) Continuing Operations
636 896 1,199 2,444 2,116 3,513 8,075 4,338 3,954 4,413 4,505
Consolidated Net Income / (Loss)
636 896 1,199 2,444 2,116 3,513 8,075 4,338 3,954 4,413 4,505
Depreciation Expense
75 105 146 148 210 236 286 341 421 483 544
Non-Cash Adjustments To Reconcile Net Income
512 605 571 440 435 297 783 1,325 1,151 901 183
Changes in Operating Assets and Liabilities, net
108 -119 -608 -837 -331 -1,428 -2,064 -990 -932 -1,376 -253
Net Cash From Investing Activities
-908 -1,047 -1,005 -1,463 -2,028 -71 -5,385 -3,785 -3,185 -2,468 -629
Net Cash From Continuing Investing Activities
-908 -1,047 -1,005 -1,463 -2,028 -71 -5,385 -3,785 -3,185 -2,468 -629
Purchase of Property, Plant & Equipment
-678 -512 -273 -383 -430 -615 -552 -590 -719 -756 -898
Acquisitions
- - - - - 0.00 0.00 -230 -55 -17 -3.30
Purchase of Investments
-557 -809 -1,277 -1,846 -3,202 -3,241 -7,048 -7,488 -11,646 -16,617 -10,958
Sale of Property, Plant & Equipment
- - - - - - - 0.00 0.00 20 0.00
Sale and/or Maturity of Investments
327 275 545 776 1,604 3,785 2,215 5,551 9,442 15,027 11,546
Other Investing Activities, net
- 0.00 0.00 -10 - 0.00 0.00 -1,027 -208 -126 -315
Net Cash From Financing Activities
-263 -701 -24 -77 -252 -1,971 -1,006 -1,009 -1,790 -2,201 -3,715
Net Cash From Continuing Financing Activities
-263 -701 -24 -77 -252 -1,971 -1,006 -1,009 -1,790 -2,201 -3,715
Repayment of Debt
-168 -46 -20 0.00 0.00 -1,500 - 0.00 0.00 -33 -10
Repurchase of Common Equity
-573 -643 0.00 -4.40 -276 -5,847 -1,645 -2,083 -2,235 -2,603 -3,439
Payment of Dividends
- - - - - - - - 0.00 0.00 -370
Issuance of Common Equity
206 127 240 115 212 2,575 1,672 1,520 1,146 1,465 636
Other Financing Activities, net
245 -143 -302 -187 -188 -681 -1,033 -446 -701 -1,029 -532
Effect of Exchange Rate Changes
- - - - - - 0.00 0.00 -0.40 -0.70 0.30
Cash Interest Paid
11 5.50 19 22 25 23 56 54 73 53 42

Quarterly Cash Flow Statements for Regeneron Pharmaceuticals

This table details how cash moves in and out of Regeneron Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents
211 578 -128 -682 84 477 604 -1,077 498 611 -153
Net Cash From Operating Activities
1,114 1,090 1,513 354 1,291 1,263 1,045 1,144 1,619 1,171 1,079
Net Cash From Continuing Operating Activities
1,114 1,090 1,513 354 1,291 1,263 1,045 1,144 1,619 1,171 1,079
Net Income / (Loss) Continuing Operations
1,008 1,160 722 1,432 1,341 918 809 1,392 1,460 845 727
Consolidated Net Income / (Loss)
1,008 1,160 722 1,432 1,341 918 809 1,392 1,460 845 727
Depreciation Expense
105 113 114 121 122 126 127 135 137 145 123
Non-Cash Adjustments To Reconcile Net Income
319 165 426 -172 61 585 119 -19 -324 408 288
Changes in Operating Assets and Liabilities, net
-318 -348 250 -1,027 -233 -367 -9.50 -363 346 -227 -60
Net Cash From Investing Activities
-496 -66 -1,687 -557 -574 351 648 -1,094 -403 220 -429
Net Cash From Continuing Investing Activities
-496 -66 -1,687 -557 -574 351 648 -1,094 -403 220 -429
Purchase of Property, Plant & Equipment
-176 -251 -134 -181 -242 -200 -229 -219 -201 -249 -231
Purchase of Investments
-3,243 -2,132 -5,658 -4,416 -4,591 -1,953 -2,539 -2,855 -3,520 -2,044 -2,756
Sale and/or Maturity of Investments
2,998 2,383 4,132 4,055 4,259 2,582 3,458 2,168 3,365 2,555 2,607
Other Investing Activities, net
-24 -62 -28 -30 - -67 -42 -188 -43 -42 -49
Net Cash From Financing Activities
-407 -446 47 -478 -634 -1,136 -1,089 -1,128 -718 -780 -802
Net Cash From Continuing Financing Activities
-407 -446 47 -478 -634 -1,136 -1,089 -1,128 -718 -780 -802
Repayment of Debt
- - 0.00 - - - -10 - - - 0.00
Repurchase of Common Equity
-547 -289 -291 -604 -735 -973 -1,041 -1,062 -664 -672 -794
Payment of Dividends
- - 0.00 - - - -94 -93 -91 -93 -98
Issuance of Common Equity
269 301 682 438 255 91 61 32 40 504 163
Other Financing Activities, net
-129 -458 -344 -312 -120 -253 -4.30 -5.60 -3.00 -519 -73
Effect of Exchange Rate Changes
-0.20 0.20 -0.50 -0.30 0.80 -0.70 0.60 0.40 -0.40 -0.30 -0.90

Annual Balance Sheets for Regeneron Pharmaceuticals

This table presents Regeneron Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
5,609 6,973 8,764 11,735 14,805 17,163 25,435 29,215 33,080 37,759 40,559
Total Current Assets
2,915 3,180 4,335 6,448 7,689 9,779 14,015 15,884 19,479 18,661 18,022
Cash & Equivalents
809 535 813 1,468 1,618 2,194 2,886 3,106 2,730 2,488 3,118
Short-Term Investments
236 503 597 1,342 1,597 1,393 2,809 4,636 8,115 6,524 5,487
Accounts Receivable
1,468 1,612 1,974 2,243 2,786 4,115 6,037 5,329 5,667 6,212 5,741
Inventories, net
239 399 726 1,151 1,416 1,917 1,951 2,402 2,581 3,087 3,201
Prepaid Expenses
164 131 225 243 274 161 332 411 387 349 475
Plant, Property, & Equipment, net
1,594 2,083 2,359 2,576 0.00 0.00 3,482 3,763 4,146 4,600 5,120
Total Noncurrent Assets
1,100 1,710 2,071 2,711 7,116 7,384 7,938 9,567 9,455 14,499 17,416
Long-Term Investments
632 864 1,487 1,755 3,257 3,136 6,838 6,592 5,397 8,900 10,261
Intangible Assets
- - - - - - 6.70 916 1,039 1,149 1,257
Noncurrent Deferred & Refundable Income Taxes
462 825 506 829 824 859 877 1,724 2,575 3,314 4,077
Other Noncurrent Operating Assets
5.81 20 78 127 3,035 3,390 216 336 444 1,136 1,821
Total Liabilities & Shareholders' Equity
5,609 6,973 8,764 11,735 14,805 17,163 25,435 29,215 33,080 37,759 40,559
Total Liabilities
1,954 2,524 2,620 2,977 3,716 6,138 6,666 6,551 7,107 8,406 9,302
Total Current Liabilities
811 1,241 1,136 1,443 2,097 2,697 3,933 3,141 3,423 3,944 4,368
Accounts Payable
644 879 178 218 418 476 564 589 607 790 939
Accrued Expenses
- - 637 772 1,211 1,644 2,207 2,074 2,358 2,527 2,876
Current Deferred Revenue
153 232 320 453 382 578 442 478 459 628 553
Other Current Liabilities
14 1.18 - - 85 0.00 720 - - - 0.00
Total Noncurrent Liabilities
1,143 1,283 1,485 1,534 1,619 3,441 2,734 3,409 3,684 4,462 4,933
Long-Term Debt
- - - - 0.00 1,979 1,980 1,981 1,983 1,984 1,986
Capital Lease Obligations
363 352 704 709 714 717 - 720 720 720 720
Noncurrent Deferred Revenue
665 831 629 464 105 58 73 70 127 186 209
Other Noncurrent Operating Liabilities
116 100 152 362 800 687 680 638 854 1,571 2,019
Total Equity & Noncontrolling Interests
3,655 4,449 6,144 8,757 11,090 11,025 18,769 22,664 25,973 29,354 31,257
Total Preferred & Common Equity
3,655 4,449 6,144 8,757 11,090 11,025 18,769 22,664 25,973 29,354 31,257
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
3,655 4,449 6,144 8,757 11,090 11,025 18,769 22,664 25,973 29,354 31,257
Common Stock
3,100 3,030 3,513 3,912 4,429 6,716 8,088 9,949 11,354 12,856 13,995
Retained Earnings
853 1,748 2,947 5,254 7,380 10,893 18,968 23,307 27,260 31,673 35,797
Treasury Stock
-306 -316 -316 -396 -740 -6,613 -8,261 -10,353 -12,560 -15,167 -18,613
Accumulated Other Comprehensive Income / (Loss)
8.57 -13 0.60 -12 21 29 -26 -239 -81 -7.90 78

Quarterly Balance Sheets for Regeneron Pharmaceuticals

This table presents Regeneron Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets
30,658 32,163 33,080 34,370 36,087 37,442 37,759 37,545 38,219 40,169 40,869
Total Current Assets
16,923 18,635 19,479 18,872 19,082 19,334 18,661 17,572 16,860 17,981 18,209
Cash & Equivalents
1,937 2,152 2,730 2,602 1,921 2,012 2,488 3,090 1,996 2,506 2,963
Short-Term Investments
6,991 7,761 8,115 7,918 7,888 7,785 6,524 5,259 5,474 5,937 5,791
Accounts Receivable
5,121 5,585 5,667 5,222 5,717 6,107 6,212 5,561 5,610 5,687 5,731
Inventories, net
2,508 2,562 2,581 2,715 2,874 3,018 3,087 3,192 3,206 3,254 3,104
Prepaid Expenses
366 575 387 415 682 412 349 469 574 596 621
Plant, Property, & Equipment, net
3,923 4,006 4,146 4,226 4,306 4,439 4,600 4,694 4,841 5,002 5,266
Total Noncurrent Assets
9,812 9,522 9,455 11,273 12,699 13,669 14,499 15,279 16,519 17,186 17,394
Long-Term Investments
6,327 5,779 5,397 6,979 7,722 8,491 8,900 9,276 10,058 10,286 9,786
Intangible Assets
953 1,017 1,039 1,059 1,102 1,120 1,149 1,167 1,352 1,381 1,287
Noncurrent Deferred & Refundable Income Taxes
2,139 2,317 2,575 2,765 2,881 3,015 3,314 3,443 3,572 3,847 4,191
Other Noncurrent Operating Assets
393 410 444 470 994 1,043 1,136 1,393 1,537 1,673 2,130
Total Liabilities & Shareholders' Equity
30,658 32,163 33,080 34,370 36,087 37,442 37,759 37,545 38,219 40,169 40,869
Total Liabilities
6,640 7,259 7,107 7,379 7,881 8,116 8,406 8,158 8,280 9,212 9,445
Total Current Liabilities
3,104 3,599 3,423 3,581 3,509 3,661 3,944 3,567 3,667 4,425 5,108
Accounts Payable
547 537 607 671 562 497 790 706 724 904 1,027
Accrued Expenses
2,176 2,645 2,358 2,393 2,361 2,537 2,527 2,242 2,461 2,976 2,724
Current Deferred Revenue
381 417 459 517 586 627 628 619 482 546 636
Other Current Liabilities
- - - - - - - - - - 720
Total Noncurrent Liabilities
3,535 3,660 3,684 3,798 4,372 4,455 4,462 4,591 4,613 4,787 4,338
Long-Term Debt
1,982 1,983 1,983 1,983 1,984 1,984 1,984 1,985 1,985 1,986 1,986
Capital Lease Obligations
720 720 720 720 720 720 720 720 720 720 0.00
Noncurrent Deferred Revenue
116 125 127 186 206 207 186 212 206 219 225
Other Noncurrent Operating Liabilities
717 832 854 909 1,463 1,544 1,571 1,674 1,702 1,862 2,126
Total Equity & Noncontrolling Interests
24,018 24,904 25,973 26,991 28,206 29,326 29,354 29,388 29,939 30,958 31,424
Total Preferred & Common Equity
24,018 24,904 25,973 26,991 28,206 29,326 29,354 29,388 29,939 30,958 31,424
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
24,018 24,904 25,973 26,991 28,206 29,326 29,354 29,388 29,939 30,958 31,424
Common Stock
10,889 11,252 11,354 11,943 12,317 12,703 12,856 13,192 13,491 13,787 14,401
Retained Earnings
25,093 26,101 27,260 27,982 29,415 30,755 31,673 32,384 33,680 35,046 36,424
Treasury Stock
-11,766 -12,271 -12,560 -12,857 -13,456 -14,192 -15,167 -16,218 -17,285 -17,944 -19,414
Accumulated Other Comprehensive Income / (Loss)
-198 -177 -81 -77 -70 60 -7.90 29 53 69 12

Annual Metrics And Ratios for Regeneron Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Regeneron Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
45.55% 18.44% 20.82% -12.37% 27.44% 29.58% 89.14% -24.26% 7.76% 8.27% 0.99%
EBITDA Growth
54.38% 9.63% 56.10% 21.38% -2.21% 53.70% 135.65% -45.61% -10.77% 13.31% 9.41%
EBIT Growth
55.19% 7.81% 57.44% 22.73% -4.74% 57.25% 142.63% -47.58% -13.13% 13.17% 9.09%
NOPAT Growth
77.61% 37.87% 33.82% 102.32% -20.66% 71.32% 134.93% -45.38% -9.95% -3.31% -16.36%
Net Income Growth
88.11% 40.79% 33.84% 103.95% -13.44% 66.05% 129.86% -46.28% -8.87% 11.61% 2.09%
EPS Growth
85.23% 39.49% 34.29% 105.90% -13.29% 65.33% 135.81% -46.89% -9.03% 10.27% 8.19%
Operating Cash Flow Growth
76.86% 11.66% -12.03% 67.94% 10.70% 7.74% 170.47% -29.18% -8.39% -3.78% 12.63%
Free Cash Flow Firm Growth
-147.11% 585.45% 31.53% 437.10% 1.11% 9.28% 300.15% -78.31% 69.96% -18.01% 7.93%
Invested Capital Growth
42.07% 29.36% 30.53% 24.02% 8.81% 31.24% 17.40% 34.26% 12.72% 13.76% 6.73%
Revenue Q/Q Growth
7.77% 2.72% 6.45% -19.16% 29.68% 7.05% 18.67% -11.21% 0.15% 2.56% 0.67%
EBITDA Q/Q Growth
5.54% 7.77% 11.01% 5.04% 9.18% 9.33% 15.41% -17.94% -3.36% -3.34% 1.85%
EBIT Q/Q Growth
5.11% 7.91% 11.52% 5.00% 9.48% 9.73% 15.77% -19.29% -3.96% -3.92% 1.68%
NOPAT Q/Q Growth
9.28% 12.45% -7.29% 39.38% -11.70% 17.71% 19.23% -23.67% -1.02% -1.01% -6.10%
Net Income Q/Q Growth
11.36% 12.30% -6.23% 35.98% -1.32% 11.32% 15.44% -19.21% -0.94% -5.20% -1.60%
EPS Q/Q Growth
11.29% 11.59% -5.74% 35.86% -1.12% 11.55% 15.19% -19.23% -0.77% -5.17% -0.81%
Operating Cash Flow Q/Q Growth
6.71% 7.88% 15.62% 7.96% 2.47% 20.40% 19.22% -11.51% -12.06% 4.08% -1.82%
Free Cash Flow Firm Q/Q Growth
-142.44% -65.54% 161.21% 15.51% 2.07% -10.61% 33.76% -35.99% -21.96% 4.19% 1.90%
Invested Capital Q/Q Growth
10.67% 31.34% -2.37% 8.67% 2.03% 12.83% 5.08% -1.06% 4.36% 2.93% 1.09%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
90.43% 93.83% 93.24% 91.89% 88.33% 86.82% 84.83% 87.18% 86.16% 86.13% 85.35%
EBITDA Margin
32.03% 29.64% 38.30% 53.05% 40.71% 48.29% 60.16% 43.21% 35.78% 37.45% 40.57%
Operating Margin
30.51% 27.38% 35.41% 49.25% 33.70% 42.09% 55.67% 38.93% 30.85% 28.10% 24.95%
EBIT Margin
30.20% 27.49% 35.82% 50.17% 37.50% 45.51% 58.38% 40.40% 32.57% 34.05% 36.77%
Profit (Net Income) Margin
15.50% 18.42% 20.41% 47.50% 32.26% 41.35% 50.25% 35.64% 30.14% 31.07% 31.41%
Tax Burden Percent
51.92% 67.34% 57.66% 95.73% 87.10% 92.20% 86.59% 89.29% 94.15% 92.32% 86.12%
Interest Burden Percent
98.85% 99.53% 98.81% 98.91% 98.77% 98.53% 99.39% 98.79% 98.29% 98.86% 99.17%
Effective Tax Rate
48.08% 32.66% 42.34% 4.27% 12.90% 7.80% 13.41% 10.71% 5.85% 7.68% 13.88%
Return on Invested Capital (ROIC)
32.60% 33.39% 34.36% 54.81% 37.62% 53.49% 101.84% 43.97% 32.48% 27.72% 21.08%
ROIC Less NNEP Spread (ROIC-NNEP)
33.86% 33.43% 34.40% 54.21% 33.64% 49.08% 97.34% 43.00% 31.34% 22.65% 12.00%
Return on Net Nonoperating Assets (RNNOA)
-12.10% -11.29% -11.74% -22.00% -16.30% -21.71% -47.63% -23.03% -16.22% -11.77% -6.21%
Return on Equity (ROE)
20.50% 22.10% 22.63% 32.81% 21.32% 31.77% 54.21% 20.94% 16.26% 15.95% 14.87%
Cash Return on Invested Capital (CROIC)
-2.16% 7.79% 7.88% 33.36% 29.18% 26.47% 85.83% 14.72% 20.51% 14.85% 14.57%
Operating Return on Assets (OROA)
26.24% 21.24% 26.73% 25.19% 18.53% 24.19% 44.05% 18.00% 13.72% 13.65% 13.47%
Return on Assets (ROA)
13.47% 14.23% 15.23% 23.85% 15.94% 21.98% 37.91% 15.88% 12.69% 12.46% 11.50%
Return on Common Equity (ROCE)
20.50% 22.10% 22.63% 32.81% 21.32% 31.77% 54.21% 20.94% 16.26% 15.95% 14.87%
Return on Equity Simple (ROE_SIMPLE)
17.40% 20.13% 19.51% 27.91% 19.08% 31.86% 43.03% 19.14% 15.22% 15.03% 0.00%
Net Operating Profit after Tax (NOPAT)
650 896 1,199 2,426 1,925 3,298 7,747 4,231 3,810 3,684 3,081
NOPAT Margin
15.84% 18.44% 20.42% 47.15% 29.35% 38.81% 48.20% 34.76% 29.05% 25.94% 21.48%
Net Nonoperating Expense Percent (NNEP)
-1.26% -0.04% -0.04% 0.60% 3.97% 4.41% 4.50% 0.97% 1.14% 5.07% 9.08%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - 16.68% 13.29% 11.49% 9.07%
Cost of Revenue to Revenue
9.57% 6.17% 6.76% 8.11% 11.67% 13.18% 15.17% 12.82% 13.84% 13.87% 14.65%
SG&A Expenses to Revenue
20.43% 24.23% 22.49% 21.91% 20.46% 15.84% 11.35% 17.38% 20.06% 20.80% 18.82%
R&D to Revenue
39.49% 42.22% 35.34% 28.54% 37.36% 32.19% 18.09% 31.61% 35.26% 36.85% 41.65%
Operating Expenses to Revenue
59.92% 66.46% 57.82% 42.63% 54.63% 44.73% 29.17% 48.25% 55.30% 58.03% 60.41%
Earnings before Interest and Taxes (EBIT)
1,239 1,336 2,104 2,582 2,459 3,867 9,383 4,918 4,272 4,835 5,275
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
1,314 1,441 2,249 2,730 2,670 4,103 9,669 5,260 4,693 5,318 5,818
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
15.46 8.70 6.57 4.62 3.72 4.68 3.62 3.47 3.68 2.67 2.60
Price to Tangible Book Value (P/TBV)
15.46 8.70 6.57 4.62 3.72 4.68 3.62 3.61 3.84 2.78 2.70
Price to Revenue (P/Rev)
13.77 7.97 6.88 7.86 6.29 6.07 4.23 6.45 7.29 5.51 5.66
Price to Earnings (P/E)
88.82 43.24 33.70 16.54 19.48 14.67 8.41 18.11 24.20 17.74 18.01
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.46%
Earnings Yield
1.13% 2.31% 2.97% 6.05% 5.13% 6.82% 11.89% 5.52% 4.13% 5.64% 5.55%
Enterprise Value to Invested Capital (EV/IC)
23.58 12.32 9.67 7.46 6.65 6.79 6.98 6.07 6.61 4.46 4.30
Enterprise Value to Revenue (EV/Rev)
13.45 7.67 6.51 7.11 5.41 5.59 3.57 5.50 6.26 4.44 4.53
Enterprise Value to EBITDA (EV/EBITDA)
41.99 25.89 16.98 13.40 13.29 11.58 5.93 12.73 17.50 11.86 11.17
Enterprise Value to EBIT (EV/EBIT)
44.52 27.91 18.16 14.16 14.42 12.29 6.11 13.61 19.23 13.04 12.32
Enterprise Value to NOPAT (EV/NOPAT)
84.89 41.62 31.86 15.07 18.43 14.41 7.40 15.82 21.56 17.12 21.08
Enterprise Value to Operating Cash Flow (EV/OCF)
41.46 25.10 29.23 16.66 14.60 18.15 8.10 13.35 17.88 14.27 13.05
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 178.40 138.93 24.76 23.75 29.12 8.79 47.27 34.13 31.96 30.50
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.10 0.11 0.11 0.08 0.06 0.24 0.11 0.12 0.10 0.09 0.09
Long-Term Debt to Equity
0.10 0.08 0.11 0.08 0.06 0.24 0.11 0.12 0.10 0.09 0.09
Financial Leverage
-0.36 -0.34 -0.34 -0.41 -0.48 -0.44 -0.49 -0.54 -0.52 -0.52 -0.52
Leverage Ratio
1.52 1.55 1.49 1.38 1.34 1.45 1.43 1.32 1.28 1.28 1.29
Compound Leverage Factor
1.50 1.55 1.47 1.36 1.32 1.42 1.42 1.30 1.26 1.27 1.28
Debt to Total Capital
9.03% 9.76% 10.27% 7.48% 6.05% 19.65% 9.54% 10.65% 9.43% 8.44% 7.97%
Short-Term Debt to Total Capital
0.00% 2.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
9.03% 7.13% 10.27% 7.48% 6.05% 19.65% 9.54% 10.65% 9.43% 8.44% 7.97%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
90.97% 90.24% 89.73% 92.51% 93.95% 80.35% 90.46% 89.35% 90.57% 91.56% 92.03%
Debt to EBITDA
0.28 0.33 0.31 0.26 0.27 0.66 0.20 0.51 0.58 0.51 0.47
Net Debt to EBITDA
-1.00 -0.99 -0.97 -1.41 -2.16 -0.98 -1.09 -2.21 -2.88 -2.86 -2.78
Long-Term Debt to EBITDA
0.28 0.24 0.31 0.26 0.27 0.66 0.20 0.51 0.58 0.51 0.47
Debt to NOPAT
0.56 0.54 0.59 0.29 0.37 0.82 0.26 0.64 0.71 0.73 0.88
Net Debt to NOPAT
-2.02 -1.59 -1.83 -1.59 -2.99 -1.22 -1.36 -2.75 -3.55 -4.13 -5.24
Long-Term Debt to NOPAT
0.56 0.39 0.59 0.29 0.37 0.82 0.26 0.64 0.71 0.73 0.88
Altman Z-Score
19.47 11.22 11.62 10.45 8.80 7.66 9.48 9.81 10.64 8.03 7.66
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.59 2.56 3.82 4.47 3.67 3.63 3.56 5.06 5.69 4.73 4.13
Quick Ratio
3.10 2.13 2.98 3.50 2.86 2.86 2.98 4.16 4.82 3.86 3.28
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-43 209 275 1,477 1,493 1,632 6,529 1,416 2,407 1,973 2,130
Operating Cash Flow to CapEx
196.30% 290.27% 479.49% 572.98% 565.64% 425.98% 1,283.08% 849.84% 639.30% 600.77% 554.20%
Free Cash Flow to Firm to Interest Expense
0.00 29.03 10.95 52.37 49.44 28.68 113.95 23.84 32.97 35.75 48.63
Operating Cash Flow to Interest Expense
0.00 206.38 52.08 77.84 80.46 46.01 123.58 84.43 62.93 80.08 113.67
Operating Cash Flow Less CapEx to Interest Expense
0.00 135.28 41.22 64.26 66.24 35.21 113.95 74.49 53.09 66.75 93.16
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.87 0.77 0.75 0.50 0.49 0.53 0.75 0.45 0.42 0.40 0.37
Accounts Receivable Turnover
3.36 3.16 3.28 2.44 2.61 2.46 3.17 2.14 2.39 2.39 2.40
Inventory Turnover
2.14 0.94 0.71 0.44 0.60 0.67 1.26 0.72 0.73 0.70 0.67
Fixed Asset Turnover
3.20 2.64 2.64 2.09 0.00 0.00 0.00 3.36 3.32 3.25 2.95
Accounts Payable Turnover
0.70 0.39 0.75 2.11 2.40 2.51 4.69 2.71 3.04 2.82 2.43
Days Sales Outstanding (DSO)
108.70 115.63 111.45 149.58 139.95 148.20 115.27 170.39 152.99 152.65 152.09
Days Inventory Outstanding (DIO)
170.76 388.47 517.24 820.62 612.24 543.00 289.60 509.14 500.76 524.93 546.28
Days Payable Outstanding (DPO)
524.02 927.55 485.91 173.28 151.78 145.62 77.83 134.88 120.19 129.30 150.16
Cash Conversion Cycle (CCC)
-244.57 -423.45 142.77 796.92 600.41 545.58 327.04 544.65 533.57 548.28 548.21
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
2,340 3,027 3,952 4,901 5,333 6,998 8,216 11,031 12,435 14,145 15,097
Invested Capital Turnover
2.06 1.81 1.68 1.16 1.28 1.38 2.11 1.26 1.12 1.07 0.98
Increase / (Decrease) in Invested Capital
693 687 924 949 432 1,666 1,218 2,815 1,403 1,711 952
Enterprise Value (EV)
55,179 37,295 38,200 36,569 35,469 47,524 57,363 66,939 82,149 63,069 64,963
Market Capitalization
56,494 38,717 40,393 40,426 41,226 51,551 67,916 78,572 95,687 78,278 81,123
Book Value per Share
$35.12 $42.18 $57.19 $80.91 $101.00 $103.32 $174.52 $208.11 $238.40 $267.12 $297.40
Tangible Book Value per Share
$35.12 $42.18 $57.19 $80.91 $101.00 $103.32 $174.46 $199.71 $228.87 $256.67 $285.44
Total Capital
4,018 4,930 6,848 9,466 11,804 13,721 20,749 25,366 28,676 32,058 33,963
Total Debt
363 481 704 709 714 2,696 1,980 2,701 2,703 2,704 2,706
Total Long-Term Debt
363 352 704 709 714 2,696 1,980 2,701 2,703 2,704 2,706
Net Debt
-1,314 -1,422 -2,193 -3,856 -5,757 -4,027 -10,553 -11,633 -13,538 -15,208 -16,160
Capital Expenditures (CapEx)
678 512 273 383 430 615 552 590 719 736 898
Debt-free, Cash-free Net Working Capital (DFCFNWC)
1,059 1,030 1,790 2,195 2,378 3,495 4,388 5,001 5,211 5,704 5,048
Debt-free Net Working Capital (DFNWC)
2,104 2,068 3,200 5,005 5,593 7,082 10,082 12,743 16,056 14,717 13,654
Net Working Capital (NWC)
2,104 1,939 3,200 5,005 5,593 7,082 10,082 12,743 16,056 14,717 13,654
Net Nonoperating Expense (NNE)
14 0.61 0.63 -18 -191 -216 -328 -107 -143 -729 -1,423
Net Nonoperating Obligations (NNO)
-1,314 -1,422 -2,193 -3,856 -5,757 -4,027 -10,553 -11,633 -13,538 -15,208 -16,160
Total Depreciation and Amortization (D&A)
75 105 146 148 210 236 286 341 421 483 544
Debt-free, Cash-free Net Working Capital to Revenue
25.80% 21.18% 30.48% 42.66% 36.27% 41.13% 27.30% 41.08% 39.73% 40.16% 35.20%
Debt-free Net Working Capital to Revenue
51.27% 42.55% 54.49% 97.26% 85.28% 83.34% 62.73% 104.68% 122.40% 103.62% 95.19%
Net Working Capital to Revenue
51.27% 39.89% 54.49% 97.26% 85.28% 83.34% 62.73% 104.68% 122.40% 103.62% 95.19%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$6.17 $8.55 $11.27 $22.65 $19.38 $32.65 $76.40 $40.51 $37.05 $40.90 $43.07
Adjusted Weighted Average Basic Shares Outstanding
103.06M 104.72M 106.34M 107.90M 109.20M 107.60M 105.70M 107.10M 106.70M 107.90M 104.60M
Adjusted Diluted Earnings per Share
$5.52 $7.70 $10.34 $21.29 $18.46 $30.52 $71.97 $38.22 $34.77 $38.34 $41.48
Adjusted Weighted Average Diluted Shares Outstanding
115.23M 116.37M 115.95M 114.80M 114.60M 115.10M 112.20M 113.50M 113.70M 115.10M 108.60M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $19.38 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
104.79M 106.08M 107.70M 109.28M 110.02M 107.13M 108.54M 109.33M 109.76M 109.32M 105.72M
Normalized Net Operating Profit after Tax (NOPAT)
650 896 1,199 2,426 1,925 3,298 7,747 4,231 3,810 3,684 3,081
Normalized NOPAT Margin
15.84% 18.44% 20.42% 47.15% 29.35% 38.81% 48.20% 34.76% 29.05% 25.94% 21.48%
Pre Tax Income Margin
29.85% 27.36% 35.40% 49.62% 37.04% 44.84% 58.03% 39.91% 32.01% 33.66% 36.47%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 185.57 83.81 91.55 81.43 67.97 163.75 82.80 58.52 87.59 120.42
NOPAT to Interest Expense
0.00 124.46 47.77 86.03 63.73 57.95 135.20 71.23 52.20 66.74 70.35
EBIT Less CapEx to Interest Expense
0.00 114.47 72.95 77.96 67.21 57.17 154.12 72.86 48.68 74.26 99.91
NOPAT Less CapEx to Interest Expense
0.00 53.36 36.91 72.45 49.51 47.15 125.57 61.30 42.35 53.41 49.84
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8.22%
Augmented Payout Ratio
90.16% 71.85% 0.00% 0.18% 13.04% 166.42% 20.38% 48.01% 56.53% 59.00% 84.55%

Quarterly Metrics And Ratios for Regeneron Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Regeneron Pharmaceuticals' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding
- - - - - - - - - - 105,719,806.00
DEI Adjusted Shares Outstanding
- - - - - - - - - - 105,719,806.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - - - - - - - 6.88
Growth Metrics
- - - - - - - - - - -
Revenue Growth
14.53% 0.58% -0.54% 12.32% 10.65% 10.33% -3.70% 3.62% 0.90% 2.51% 19.04%
EBITDA Growth
-23.72% -11.32% -14.82% 46.37% 31.97% -14.38% 25.24% -6.02% 17.86% 9.67% -7.04%
EBIT Growth
-26.00% -13.13% -18.17% 49.11% 33.51% -16.92% 27.47% -7.34% 18.30% 9.01% -7.62%
NOPAT Growth
-5.48% -5.14% -14.20% 3.51% 5.07% -3.52% -31.71% 5.12% -19.73% -24.92% 6.38%
Net Income Growth
-23.40% -3.13% -11.71% 47.90% 33.02% -20.86% 12.01% -2.84% 8.91% -7.97% -10.08%
EPS Growth
-23.76% -2.58% -12.55% 46.00% 29.81% -20.47% 15.95% 3.22% 18.02% -4.19% -7.15%
Operating Cash Flow Growth
77.18% -36.64% 10.60% -65.38% 15.88% 15.89% -30.90% 223.28% 25.36% -7.29% 3.23%
Free Cash Flow Firm Growth
110.72% 76.37% 85.95% 15.49% -416.67% -81.35% -593.53% 22.92% 55.59% 68.57% 109.13%
Invested Capital Growth
6.86% 12.72% 9.18% 16.68% 15.34% 13.76% 18.62% 12.99% 8.67% 6.73% 2.79%
Revenue Q/Q Growth
6.48% 2.13% -8.42% 12.79% 4.89% 1.84% -20.07% 21.36% 2.14% 3.46% -7.18%
EBITDA Q/Q Growth
2.42% 3.64% -35.03% 112.25% -7.66% -32.76% -4.97% 59.27% 15.80% -37.43% -19.45%
EBIT Q/Q Growth
2.43% 3.31% -38.52% 129.20% -8.28% -35.72% -5.67% 66.61% 17.10% -40.77% -20.06%
NOPAT Q/Q Growth
10.89% -2.47% -21.24% 21.53% 12.55% -10.45% -44.25% 87.08% -14.05% -16.25% -21.01%
Net Income Q/Q Growth
4.07% 15.06% -37.74% 98.38% -6.40% -31.55% -11.88% 72.08% 4.92% -42.15% -13.90%
EPS Q/Q Growth
4.59% 14.85% -38.59% 97.93% -7.01% -29.64% -10.47% 76.20% 6.32% -42.88% -13.24%
Operating Cash Flow Q/Q Growth
8.99% -2.21% 38.80% -76.60% 264.75% -2.20% -17.24% 9.50% 41.45% -27.68% -7.84%
Free Cash Flow Firm Q/Q Growth
121.10% -273.20% 40.25% -286.94% 20.92% 0.81% -128.51% 57.00% 54.43% 29.82% 166.40%
Invested Capital Q/Q Growth
3.92% 4.36% -1.92% 9.69% 2.72% 2.93% 2.27% 4.49% -1.21% 1.09% -1.50%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
87.02% 84.95% 86.21% 86.46% 86.80% 85.08% 84.67% 85.58% 86.11% 84.95% 81.43%
EBITDA Margin
36.70% 37.24% 26.42% 49.72% 43.77% 28.90% 34.36% 45.09% 51.12% 30.92% 26.83%
Operating Margin
33.04% 28.33% 23.89% 30.15% 31.70% 26.13% 19.54% 29.37% 27.35% 22.65% 17.83%
EBIT Margin
33.56% 33.95% 22.79% 46.32% 40.50% 25.56% 30.17% 41.42% 47.48% 27.18% 23.41%
Profit (Net Income) Margin
29.97% 33.77% 22.96% 40.38% 36.03% 24.22% 26.70% 37.86% 38.89% 21.74% 20.17%
Tax Burden Percent
90.73% 101.05% 103.04% 87.97% 89.79% 95.78% 89.36% 91.63% 82.80% 80.92% 87.49%
Interest Burden Percent
98.42% 98.43% 97.75% 99.10% 99.08% 98.92% 99.05% 99.76% 98.92% 98.84% 98.47%
Effective Tax Rate
9.27% -1.05% -3.04% 12.03% 10.21% 4.22% 10.64% 8.37% 17.20% 19.08% 12.51%
Return on Invested Capital (ROIC)
34.04% 32.00% 27.60% 28.81% 30.72% 26.75% 18.45% 26.85% 22.50% 17.98% 15.87%
ROIC Less NNEP Spread (ROIC-NNEP)
34.04% 30.60% 27.99% 25.22% 28.75% 26.96% 16.56% 24.13% 18.64% 17.14% 14.82%
Return on Net Nonoperating Assets (RNNOA)
-17.10% -15.84% -15.03% -13.22% -15.15% -14.01% -8.73% -12.31% -9.78% -8.87% -7.67%
Return on Equity (ROE)
16.94% 16.17% 12.57% 15.59% 15.57% 12.74% 9.72% 14.54% 12.73% 9.11% 8.20%
Cash Return on Invested Capital (CROIC)
26.74% 20.51% 22.69% 14.22% 14.76% 14.85% 8.91% 12.46% 14.58% 14.57% 18.47%
Operating Return on Assets (OROA)
14.69% 14.30% 9.27% 18.72% 16.11% 10.25% 11.82% 15.85% 17.43% 9.96% 8.91%
Return on Assets (ROA)
13.12% 14.22% 9.34% 16.32% 14.34% 9.71% 10.46% 14.48% 14.28% 7.96% 7.68%
Return on Common Equity (ROCE)
16.94% 16.17% 12.57% 15.59% 15.57% 12.74% 9.72% 14.54% 12.73% 9.11% 8.20%
Return on Equity Simple (ROE_SIMPLE)
16.03% 0.00% 14.29% 15.32% 15.87% 0.00% 15.31% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
1,008 983 774 941 1,059 948 529 989 850 712 562
NOPAT Margin
29.98% 28.63% 24.62% 26.53% 28.47% 25.03% 17.46% 26.91% 22.65% 18.33% 15.60%
Net Nonoperating Expense Percent (NNEP)
0.00% 1.40% -0.39% 3.59% 1.97% -0.21% 1.88% 2.71% 3.86% 0.85% 1.05%
Return On Investment Capital (ROIC_SIMPLE)
- 3.43% - - - 2.96% 1.65% 3.03% 2.53% 2.10% 1.68%
Cost of Revenue to Revenue
12.98% 15.05% 13.79% 13.54% 13.20% 14.92% 15.33% 14.42% 13.89% 15.05% 18.57%
SG&A Expenses to Revenue
19.05% 21.48% 21.91% 21.39% 19.20% 20.91% 20.90% 17.25% 17.52% 19.95% 17.96%
R&D to Revenue
34.95% 35.15% 39.92% 34.50% 35.68% 37.63% 44.23% 38.95% 41.50% 42.34% 45.64%
Operating Expenses to Revenue
53.98% 56.62% 62.31% 56.31% 55.10% 58.95% 65.13% 56.21% 58.76% 62.30% 63.60%
Earnings before Interest and Taxes (EBIT)
1,129 1,166 717 1,643 1,507 969 914 1,522 1,783 1,056 844
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
1,234 1,279 831 1,764 1,629 1,095 1,041 1,657 1,919 1,201 967
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.59 3.68 3.89 4.11 3.95 2.67 2.36 1.89 1.93 2.60 2.60
Price to Tangible Book Value (P/TBV)
3.74 3.84 4.04 4.27 4.11 2.78 2.46 1.98 2.01 2.70 2.71
Price to Revenue (P/Rev)
6.82 7.29 8.00 8.59 8.37 5.51 4.92 3.99 4.18 5.66 5.47
Price to Earnings (P/E)
22.38 24.20 27.18 26.80 24.90 17.74 15.41 12.71 13.02 18.01 18.47
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.14% 0.34% 0.47% 0.46% 0.46%
Earnings Yield
4.47% 4.13% 3.68% 3.73% 4.02% 5.64% 6.49% 7.87% 7.68% 5.55% 5.42%
Enterprise Value to Invested Capital (EV/IC)
6.41 6.61 7.38 7.55 7.30 4.46 3.76 2.77 2.92 4.30 4.38
Enterprise Value to Revenue (EV/Rev)
5.83 6.26 6.88 7.49 7.24 4.44 3.86 2.94 3.06 4.53 4.37
Enterprise Value to EBITDA (EV/EBITDA)
15.72 17.50 19.80 19.77 18.23 11.86 9.84 7.72 7.63 11.17 11.34
Enterprise Value to EBIT (EV/EBIT)
17.16 19.23 21.90 21.70 19.93 13.04 10.81 8.52 8.40 12.32 12.51
Enterprise Value to NOPAT (EV/NOPAT)
19.83 21.56 24.50 27.45 26.95 17.12 15.74 11.92 13.28 21.08 20.92
Enterprise Value to Operating Cash Flow (EV/OCF)
14.61 17.88 19.01 24.81 23.61 14.27 13.77 8.82 8.59 13.05 12.99
Enterprise Value to Free Cash Flow (EV/FCFF)
24.76 34.13 33.98 57.18 52.96 31.96 45.82 23.59 20.85 30.50 24.04
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.11 0.10 0.10 0.10 0.09 0.09 0.09 0.09 0.09 0.09 0.06
Long-Term Debt to Equity
0.11 0.10 0.10 0.10 0.09 0.09 0.09 0.09 0.09 0.09 0.06
Financial Leverage
-0.50 -0.52 -0.54 -0.52 -0.53 -0.52 -0.53 -0.51 -0.52 -0.52 -0.52
Leverage Ratio
1.29 1.28 1.28 1.28 1.28 1.28 1.28 1.28 1.29 1.29 1.29
Compound Leverage Factor
1.27 1.26 1.25 1.27 1.27 1.27 1.26 1.27 1.27 1.28 1.27
Debt to Total Capital
9.79% 9.43% 9.10% 8.75% 8.44% 8.44% 8.43% 8.29% 8.04% 7.97% 5.95%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
9.79% 9.43% 9.10% 8.75% 8.44% 8.44% 8.43% 8.29% 8.04% 7.97% 5.95%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
90.21% 90.57% 90.90% 91.25% 91.56% 91.56% 91.57% 91.71% 91.96% 92.03% 94.06%
Debt to EBITDA
0.56 0.58 0.59 0.53 0.49 0.51 0.49 0.50 0.47 0.47 0.35
Net Debt to EBITDA
-2.67 -2.88 -3.25 -2.90 -2.83 -2.86 -2.70 -2.73 -2.81 -2.78 -2.88
Long-Term Debt to EBITDA
0.56 0.58 0.59 0.53 0.49 0.51 0.49 0.50 0.47 0.47 0.35
Debt to NOPAT
0.70 0.71 0.74 0.73 0.73 0.73 0.78 0.77 0.82 0.88 0.64
Net Debt to NOPAT
-3.37 -3.55 -4.02 -4.03 -4.19 -4.13 -4.31 -4.22 -4.88 -5.24 -5.32
Long-Term Debt to NOPAT
0.70 0.71 0.74 0.73 0.73 0.73 0.78 0.77 0.82 0.88 0.64
Altman Z-Score
9.60 10.33 10.65 11.00 10.72 7.69 7.21 6.26 6.01 7.31 7.25
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
5.18 5.69 5.27 5.44 5.28 4.73 4.93 4.60 4.06 4.13 3.57
Quick Ratio
4.31 4.82 4.40 4.43 4.34 3.86 3.90 3.57 3.19 3.28 2.84
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
243 -420 -251 -972 -768 -762 -1,742 -749 -341 -240 159
Operating Cash Flow to CapEx
633.13% 433.45% 1,129.57% 196.12% 533.77% 632.67% 455.78% 522.56% 803.72% 470.73% 467.87%
Free Cash Flow to Firm to Interest Expense
13.63 -22.97 -15.60 -65.66 -55.69 -72.60 -200.21 -208.07 -17.68 -19.64 12.33
Operating Cash Flow to Interest Expense
62.60 59.55 93.94 23.92 93.57 120.27 120.13 317.89 83.87 95.96 83.64
Operating Cash Flow Less CapEx to Interest Expense
52.71 45.81 85.63 11.72 76.04 101.26 93.77 257.06 73.44 75.57 65.76
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.44 0.42 0.41 0.40 0.40 0.40 0.39 0.38 0.37 0.37 0.38
Accounts Receivable Turnover
2.35 2.39 2.53 2.49 2.37 2.39 2.61 2.51 2.42 2.40 2.64
Inventory Turnover
0.74 0.73 0.70 0.69 0.69 0.70 0.68 0.67 0.66 0.67 0.73
Fixed Asset Turnover
3.40 3.32 3.23 3.28 3.28 3.25 3.16 3.11 3.02 2.95 3.00
Accounts Payable Turnover
3.43 3.04 2.82 3.37 3.72 2.82 2.91 3.19 2.97 2.43 2.66
Days Sales Outstanding (DSO)
155.13 152.99 144.06 146.64 154.09 152.65 139.71 145.43 151.07 152.09 138.13
Days Inventory Outstanding (DIO)
493.53 500.76 523.40 525.91 529.81 524.93 538.77 540.93 549.95 546.28 498.32
Days Payable Outstanding (DPO)
106.38 120.19 129.41 108.38 98.17 129.30 125.57 114.39 122.84 150.16 137.13
Cash Conversion Cycle (CCC)
542.27 533.57 538.04 564.17 585.74 548.28 552.91 571.97 578.17 548.21 499.31
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
11,915 12,435 12,196 13,378 13,743 14,145 14,467 15,116 14,934 15,097 14,870
Invested Capital Turnover
1.14 1.12 1.12 1.09 1.08 1.07 1.06 1.00 0.99 0.98 1.02
Increase / (Decrease) in Invested Capital
765 1,403 1,025 1,913 1,828 1,711 2,271 1,738 1,192 952 403
Enterprise Value (EV)
76,350 82,149 90,065 100,980 100,300 63,069 54,416 41,859 43,570 64,963 65,130
Market Capitalization
89,339 95,687 104,860 115,808 115,883 78,278 69,337 56,682 59,594 81,123 81,683
Book Value per Share
$229.41 $238.40 $250.38 $255.98 $266.03 $267.12 $268.81 $277.30 $292.09 $297.40 $297.23
Tangible Book Value per Share
$220.04 $228.87 $240.56 $245.98 $255.87 $256.67 $258.14 $264.78 $279.06 $285.44 $285.06
Total Capital
27,607 28,676 29,695 30,910 32,030 32,058 32,092 32,644 33,663 33,963 33,410
Total Debt
2,703 2,703 2,703 2,704 2,704 2,704 2,705 2,705 2,706 2,706 1,986
Total Long-Term Debt
2,703 2,703 2,703 2,704 2,704 2,704 2,705 2,705 2,706 2,706 1,986
Net Debt
-12,990 -13,538 -14,795 -14,828 -15,583 -15,208 -14,921 -14,823 -16,024 -16,160 -16,554
Capital Expenditures (CapEx)
176 251 134 181 242 200 229 219 201 249 231
Debt-free, Cash-free Net Working Capital (DFCFNWC)
5,123 5,211 4,771 5,764 5,876 5,704 5,656 5,723 5,112 5,048 4,348
Debt-free Net Working Capital (DFNWC)
15,036 16,056 15,291 15,573 15,673 14,717 14,005 13,193 13,556 13,654 13,102
Net Working Capital (NWC)
15,036 16,056 15,291 15,573 15,673 14,717 14,005 13,193 13,556 13,654 13,102
Net Nonoperating Expense (NNE)
0.18 -177 52 -491 -281 31 -280 -402 -610 -133 -165
Net Nonoperating Obligations (NNO)
-12,990 -13,538 -14,795 -14,828 -15,584 -15,208 -14,921 -14,823 -16,024 -16,160 -16,554
Total Depreciation and Amortization (D&A)
105 113 114 121 122 126 127 135 137 145 123
Debt-free, Cash-free Net Working Capital to Revenue
39.11% 39.73% 36.42% 42.73% 42.44% 40.16% 40.15% 40.26% 35.88% 35.20% 29.14%
Debt-free Net Working Capital to Revenue
114.80% 122.40% 116.72% 115.45% 113.18% 103.62% 99.43% 92.81% 95.14% 95.19% 87.81%
Net Working Capital to Revenue
114.80% 122.40% 116.72% 115.45% 113.18% 103.62% 99.43% 92.81% 95.14% 95.19% 87.81%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$9.48 $10.88 $6.70 $13.25 $12.40 $8.55 $7.58 $13.24 $14.09 $8.16 $6.99
Adjusted Weighted Average Basic Shares Outstanding
106.30M 106.70M 107.80M 108.10M 108.10M 107.90M 106.70M 105.10M 103.60M 104.60M 104M
Adjusted Diluted Earnings per Share
$8.89 $10.21 $6.27 $12.41 $11.54 $8.12 $7.27 $12.81 $13.62 $7.78 $6.75
Adjusted Weighted Average Diluted Shares Outstanding
113.40M 113.70M 115.10M 115.40M 116.20M 115.10M 111.20M 108.60M 107.20M 108.60M 107.70M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
108.95M 109.76M 110.19M 110.23M 109.89M 109.32M 107.97M 105.99M 105.10M 105.72M 104.84M
Normalized Net Operating Profit after Tax (NOPAT)
1,008 681 526 941 1,059 948 529 989 850 712 562
Normalized NOPAT Margin
29.98% 19.83% 16.72% 26.53% 28.47% 25.03% 17.46% 26.91% 22.65% 18.33% 15.60%
Pre Tax Income Margin
33.03% 33.42% 22.28% 45.90% 40.13% 25.29% 29.88% 41.32% 46.97% 26.87% 23.05%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
63.40 63.71 44.52 111.01 109.19 92.25 105.02 422.86 92.36 86.55 65.43
NOPAT to Interest Expense
56.63 53.72 48.09 63.58 76.75 90.33 60.77 274.77 44.05 58.36 43.60
EBIT Less CapEx to Interest Expense
53.52 49.97 36.21 98.81 91.66 73.24 78.67 362.03 81.93 66.16 47.56
NOPAT Less CapEx to Interest Expense
46.74 39.98 39.77 51.38 59.22 71.32 34.42 213.93 33.62 37.98 25.73
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8.22% 8.46%
Augmented Payout Ratio
59.56% 56.53% 47.06% 40.05% 41.24% 59.00% 74.53% 85.48% 81.69% 84.55% 80.61%

Financials Breakdown Chart

Key Financial Trends

Here’s a concise four-year look at Regeneron Pharmaceuticals (REGN) using the provided quarterly data for 2022–2025. The focus is on trends in revenue, profitability, cash flow, and the balance sheet that may matter to retail investors.

  • Revenue trend and top-line momentum: Regeneron’s quarterly revenue in 2025 progressed from about 3.03B (Q1) to 3.88B (Q4), indicating ongoing demand strength and a positive revenue trajectory versus 2022–2024 sales levels.
  • Very high gross margins: Gross margin consistently sits in the mid‑80% range across periods (e.g., ~84.9% in Q4 2025), signaling strong pricing power and efficient production relative to cost of goods sold.
  • Solid operating cash flow: Operating cash flow remained robust in 2025, with net cash from continuing operating activities roughly 1.05B (Q1), 1.14B (Q2), 1.62B (Q3), and 1.17B (Q4). This supports ongoing R&D and capital returns.
  • Strong balance sheet and equity base: As of 2025, Total Assets near 40B and Total Equity around 29–30B, with long‑term debt ~2B and modest leverage, reflecting a stable financial position.
  • Liquidity and investment capacity: REGN shows substantial liquidity (cash and investments) to fund pipeline work and potential strategic moves (e.g., 2025 current assets around 18B with meaningful cash and long‑term investments).
  • Shareholder returns and capital discipline: The company continues to return capital through dividends and occasional share repurchases (e.g., dividends per share around $0.88 in 2025 Q2), signaling confidence in cash generation and a willingness to return value.
  • High and persistent R&D spend: R&D expenses run at roughly 1.3B–1.6B per quarter in 2025, underscoring Regeneron’s focus on the long-term growth engine of its pipeline, which can exert near-term margin pressure but is essential for future growth.
  • Investing activity intensity remains elevated: 2025 investing activity shows sizable outflows for purchases of investments and PP&E, complemented by inflows from sales/maturities of investments, indicating active portfolio management and capacity to deploy capital.
  • Earnings volatility in late 2025: Q4 2025 net income (~0.845B) dipped versus prior quarters (e.g., Q3 2025) and was lower than the year-ago quarter, suggesting some near-term earnings softness.
  • Financing cash outflows pressuring near-term liquidity: Net cash used in financing activities remained negative in 2025 due to share repurchases and dividends (e.g., Q4 2025 financing cash flow around -0.78B), reducing cash reserves in the near term.
05/25/26 04:47 PM ETAI Generated. May Contain Errors.

Regeneron Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Regeneron Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Regeneron Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of $4.50 billion in 2025, rising from $636.06 million in 2015. The previous period was $4.41 billion in 2024. See Regeneron Pharmaceuticals' forecast for analyst expectations on what's next for the company.

Regeneron Pharmaceuticals' total operating income in 2025 was $3.58 billion, based on the following breakdown:
  • Total Gross Profit: $12.24 billion
  • Total Operating Expenses: $8.66 billion

Over the last 10 years, Regeneron Pharmaceuticals' total revenue changed from $4.10 billion in 2015 to $14.34 billion in 2025, a change of 249.5%.

Regeneron Pharmaceuticals' total liabilities were at $9.30 billion at the end of 2025, a 10.7% increase from 2024, and a 376.0% increase since 2015.

In the past 10 years, Regeneron Pharmaceuticals' cash and equivalents has ranged from $535.20 million in 2016 to $3.12 billion in 2025, and is currently $3.12 billion as of their latest financial filing in 2025.

Over the last 10 years, Regeneron Pharmaceuticals' book value per share changed from 35.12 in 2015 to 297.40 in 2025, a change of 746.8%.



Financial statements for NASDAQ:REGN last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners